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The ultimate preoperative C-reactive 
protein-to-albumin ratio is a prognostic factor 
for survival after pancreatic cancer resection
Laura van Wijk1†, Guus W. de Klein2†, Matthijs A. Kanters1, Gijs A. Patijn2 and Joost M. Klaase1*
Abstract 
Background: Emerging evidence indicates that an elevated C-reactive protein-to-albumin ratio (CAR) may be associ-
ated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Further evidence showing that this ratio has 
significant prognostic value could contribute to current prediction models and clinical decision-making.
Methods: Data were analysed of consecutive patients who underwent curative pancreatic resection between 2013 
and 2018 and were histologically diagnosed with PDAC. We investigated the relation between the ultimate preopera-
tive CAR and overall survival.
Results: A total of 163 patients were analysed. Median overall survival was 18 months (IQR 9–36). Multivariate 
analysis demonstrated that a higher CAR (HR 1.745, P = 0.004), a higher age (HR 1.062, P < 0.001), male sex (HR 1.977, 
P = 0.001), poor differentiation grade (HR 2.812, P < 0.001), and positive para-aortic lymph node(s) (HR 4.489, P < 0.001) 
were associated with a lower overall survival. Furthermore, a CAR ≥ 0.2 was associated with decreased overall survival 
(16 vs. 26 months, P = 0.003).
Conclusion: We demonstrated that an ultimate preoperative elevated CAR is an independent indicator of decreased 
overall survival after resection for PDAC. The preoperative CAR may be of additional value to the current prediction 
models.
Keywords: Albumin, C-reactive protein, Albumin, CAR , Modified Glasgow Prognostic Score, Pancreatic cancer, 
Survival
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-
related deaths worldwide, with a 5-year survival rate of 
9% for all stages combined [1]. For pancreatic tumours, 
surgical resection is the mainstay of treatment while 
(neo-)adjuvant therapy is gaining ground. Since morbid-
ity and mortality rates after surgery are high, there is a 
need for identifying preoperative biomarkers that would 
enable better stratification of patients who may benefit 
from surgery.
In recent years, emerging evidence has shown the 
potential value of a variety of systemic inflammation-
based prognostic scores in pancreatic cancer [2–7]. 
Serum elevation of C-reactive protein (CRP), an acute-
phase protein, has been shown to be a prognostic indi-
cator in a variety of neoplasms [8–11]. Moreover, 
hypoalbuminemia brought about by malnutrition and 
related to cachexia has been reported to be correlated 
with an unfavourable prognosis of gastrointestinal 
tumours [12, 13].
An elevated C-reactive protein-to-albumin ratio (CAR) 
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Prognostic Score (mGPS) seems to be potentially useful 
biomarkers for survival, but the evidence remains contro-
versial [2, 3, 6, 14]. The mGPS combines the serum eleva-
tion of CRP and the decrease in albumin concentration, 
whereas the CAR is a continuous and more quantitative 
measure. Two recent meta-analyses showed that CAR 
was a useful prognostic factor of outcome in patients 
with pancreatic cancer; however, both studies included 
only studies in Asian populations [15, 16]. Furthermore, 
there is no consensus about the optimal cut-off value 
of CAR. The cut-off value of CAR ranged between 0.04 
and 3.85 within the included studies in the meta-analysis 
from Zang et al. [16]. Currently, the most reliable prog-
nostic factors for survival after PDAC are tumour size, 
lymph node status, resection margin and differentiation 
grade [17]. However, these prognostic factors rely on 
surgical exploration [5]. Further evidence demonstrat-
ing that the CAR can predict survival may contribute to 
current prediction models and support clinical (shared) 
decision-making. The aim of our study was to investigate 
the prognostic value of the ultimate preoperative CAR 
and the optimal cut-off value after resection for PDAC as 
compared with several established prognostic factors.
Methods
Patients
Between January 2013 and December 2018, all consecu-
tive patients who underwent pancreatic resection and 
were pathologically diagnosed with PDAC at the Uni-
versity Medical Centre Groningen, the Netherlands, 
or the Isala clinics, the Netherlands, were included in 
the present study. All medical records were retrospec-
tively reviewed. Patients were excluded if data relating 
to their preoperative CRP or albumin were missing or if 
they already had metastatic disease at the time of resec-
tion. All patients were followed up until October 2019 
or death. Survival status was assured using the national 
Personal Records Database. This study was approved by 
the Institutional Review Boards of the University Medical 
Centre Groningen and Isala Zwolle (research registration 
number: 201900699).
Data collection
Baseline characteristics were collected from the elec-
tronic medical record system. Laboratory tests were 
routinely conducted for each patient preoperatively. The 
laboratory results closest to the date of surgery were 
used for analysis. The following laboratory tests were 
conducted: CA 19-9, CEA, haemoglobin, bilirubin, CRP 
and albumin. The CAR was calculated by dividing the 
serum-CRP level by the serum-albumin level [2, 3]. The 
mGPS was calculated according to the following method: 
patients with an albumin level greater than  35  g/L and 
a CRP level less than < 10  mg/L were scored 0; patients 
with only an elevated CRP (> 1  mg/dL) were scored 1; 
and patients with low albumin (< 3.5 g/dL) and high CRP 
(> 1  mg/dL) were scored 2 [18]. Patients’ preoperative 
physical performance was determined according to the 
Eastern Cooperative Oncology Group (ECOG) [19] scale 
and the ASA-score. The type of pancreatic resection was 
selected based on tumour location and was classified into 
two groups: pancreatic head resections (pylorus-preserv-
ing pancreatoduodenectomy, or Whipple procedure) 
and other types of pancreatic resection (distal pancrea-
tectomy, central pancreatectomy, total pancreatectomy). 
Postoperative complications were categorised into minor 
(Clavien–Dindo 1–2) and major complications (Clavien–
Dindo 3–5). Overall survival time was defined as the time 
between date of surgery and date of the final follow-up or 
date of death.
Statistical analysis
Discrete variables were described as total and percent-
age, and continuous variables as median and interquartile 
range (IQR). The primary outcome was overall survival 
after pancreatic resection with curative intention. Uni-
variate Cox regression was used to identify possible 
prognostic factors (i.e., when the P value was below 0.1). 
These variables, along with known prognostic factors 
in pancreatic cancer, were included in a stepwise multi-
variate Cox proportional-hazard regression analysis to 
ascertain independent prognostic factors. For the CAR, 
the optimal cut-off point was estimated with a receiver 
operating characteristic (ROC) curve using Youden’s 
index. The resulting bivariate variable (high or low ratio) 
was also tested for prognostic value in overall survival. 
Additionally, baseline and clinicopathological character-
istics were tested on difference in patients with low and 
high CAR (Chi-square test, Fischer’s exact test, Mann–
Whitney U test, as appropriate). P values under the sig-
nificance level of 0.05 were considered significant. For all 




A total of 207 patients underwent resection of histo-
logically confirmed PDAC at our institutes from 2013 
to 2018. In 40 patients, CRP or albumin were not deter-
mined preoperatively. Additionally, four patients were 
retrospectively found to have metastatic disease at the 
time of resection (two pulmonary, one hepatic, and one 
omental metastasis). This left 163 individuals resected 
with curative intent for our study population (Fig. 1).
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Baseline and clinicopathological characteristics
Baseline and clinicopathological characteristics are 
presented in Table  1. Postoperative major morbidity 
occurred in 26 patients (16%), and the mortality rates 
within 30 and 90 days were one (0.6%) and nine (5.5%), 
respectively. Differences in baseline and clinicopatho-
logical characteristics between patients with low (< 0.2) 
and high CAR (≥ 0.2) are also presented in Table  1. 
Mean haemoglobin was lower in patients with high CAR 
(P < 0.001), and patients with high CAR had a higher 
metastatic lymph node ratio. Although the type of resec-
tion appeared to be different between patients with high 
and low CAR, when grouping the resections into pan-
creatoduodenectomy (pancreas-head tumours) and 
other pancreatic resections, no significant difference was 
observed (P = 0.112).
Univariate and multivariate analyses using Cox multiple 
regression for overall survival
Median overall survival was 18 months (IQR 9–36) in the 
study population. Univariate Cox proportional-hazard 
regression was used to identify variables that were pos-
sibly associated with overall survival (Table 2). Stepwise 
multivariate Cox regression was performed using the 
variables sex, age, ECOG performance grade, haemo-
globin, CAR, neo-adjuvant therapy, type of resection, 
tumour size, tumour differentiation grade, metastatic 
lymph node ratio, para-aortic lymph node status, and 
radicality. The ultimate proportional-hazard model was 
significant (P < 0.001) and consisted of sex, age, CAR, dif-
ferentiation grade, and para-aortic lymph node status. 
A higher CAR was independently associated with lower 
survival; the hazard ratio was 1.745 (95% CI 1.200–2.539, 
P = 0.004). Due to significant collinearity with CRP and 
albumin, haemoglobin level was analysed separately, and 
stepwise Cox regression demonstrated that haemoglo-
bin was not significantly associated with survival. Fur-
thermore, when analysing CRP and albumin separately 
in multivariate analysis, only CRP was independently 
associated with survival (HR 1.006, 95% CI 1.006–1.027, 
P = 0.002). Additionally, when replacing the CAR by the 
mGPS, the variable mGPS ended in the ultimate regres-
sion model, but was non-significant (P = 0.077).
Determination of the cut‑off point for the CAR 
The mean CAR was 0.38 (SD 0.54); the median CAR was 
0.16 (IQR 0.07–0.42). The optimal cut-off for the CAR 
ratio in predicting overall mortality was estimated using 
a ROC curve. Maximum sensitivity and specificity were 
found at a ratio of 0.2, which corresponded with a sen-
sitivity of 54% and a specificity 69%, a positive predic-
tive value of 78%, and a negative predictive value of 42% 
(Table 3).
Overall survival
Median overall survival in patients with a low CAR was 
26 months (IQR 11–56), and in patients with a high CAR 
16 months (IQR 7–24). The final model using a bivariate 
variable of low (< 0.2) and high (≥ 0.2) CAR revealed that 
this variable was an independent prognostic factor as 
well (P < 0.001, HR 2.129, 95% CI 1.395–3.251). Survival 
was lower in patients with a high CAR (Fig. 2).
Discussion
Our results demonstrated that a higher CAR together 
with a higher age, male sex, poor differentiation grade 
and positive para-aortic lymph node(s) was associated 
with a lower overall survival. A CAR above 0.2 is asso-
ciated with a decreased overall survival in patients with 
PDAC after curative pancreatic resection. Corresponding 
with the previous literature, in our study, the CAR was 
an independent prognostic factor for overall survival in 
patients resected for PDAC [15, 16]. In addition, previ-
ous studies have shown the prognostic value of the mGPS 
on overall survival of patients with PDAC [20–22]. In 
our cohort, however, the mGPS was not an independ-
ent prognostic factor for overall survival, which was 
consistent with some previous studies [6, 14] although 
a prognostic trend was present. This might indicate that 
the CAR, being a continuous variable, may be a superior 
predictor if it is not condensed into a score or cut-off 
level. Therefore, we used the CAR as a continuous vari-
able in the multivariate analysis. Doing so, we were more 
able to show a correlation between CAR and survival: 
the higher the ratio, the worse the predicted survival. In 
our cohort, maximum sensitivity (54%) and specificity 
Fig. 1 Flowchart of patient inclusion PDAC pancreatic ductal 
adenocarcinoma, CRP C-reactive protein
Page 4 of 9van Wijk et al. Eur J Med Res           (2020) 25:46 





n = 90 (55%)
CAR ≥ 0.2
n = 73 (45%)
P value
Sex 0.875
 Male 87 49 (56%) 38 (44%)
 Female 76 41(54%) 35 (46%)
Age, years (mean, SD) 66 (± 9.7) 65 (± 9.7) 67 (± 9.7) 0.591
ASA 0.055
 I 12 7 (58%) 5 (42%)
 II 121 73 (60%) 48 (40%)
 III 29 10 (34%) 19 (66%)
 IV 1 0 (0%) 1 (100%)
ECOG grade 11 unknown 45 (59%) 31 (41%) 0.380
 0 76 29 (52%) 27 (48%)
 1 56 7 (50%) 7 (50%)
 2 14 1 (20%) 4 (80%)
 3 5 1 (100%) 0 (0%)
 4 1
Haemoglobin, g/dL (mean, SD) 12.9 (± 1.6) 13.4 (± 1.5) 12.1 (± 1.6) < 0.001
CEA, ng/ml (median, IQR) 4.1 (2.2–6.7) 4.5 (2.2–6.6) 3.2 (2.2–7.5) 0.577
CA 19-9, U/ml (median, IQR) 246 (60–936) 342 (54–867) 133 (62–1092) 0.800
Supplementary nutrition 38 unknown
 No 61 39 (64%) 22 (36%) 0.398
 Enteral 57 31 (54%) 26 (46%)
 Parenteral 7 3 (43%) 4 (57%)
Neoadjuvant therapy 0.692
 No 157 86 (55%) 71 (45%)
 Yes 6 4 (67%) 2 (33%)
Approach
 Open or conversion 154 85 (55%) 69 (45%) 1.000
 Laparoscopy 9 5 (56%) 4 (44%)
Type of resection
 PPPD 106 59 (56%) 47 (44%) 0.043a
 PD (Whipple’s) 24 9 (37%) 15 (63%)
 Distal pancreas resection 22 17 (77%) 5 (23%)
 Central pancreas resection 2 0 (0%) 2 (100%)
 Total pancreatectomy 9 5 (56%) 4 (44%)
Complication
 Clavien–Dindo 0–2 137 76 (55%) 61 (45%) 1.000
 Clavien–Dindo 3–5 26 14 (54%) 12 (46%)
Tumour size in mm (median, IQR) 30 (25–40) 30 (25–40) 35 (25–40) 0.477
Differentiation grade 25 unknown
 Well or moderate 88 49 (56%) 39 (44%) 0.861
 Poorly 50 27 (54%) 23 (46%)
Metastatic lymph nodes
 < 5 108 64 (59%) 44 (41%) 0.183
 ≥ 5 55 26 (47%) 29 (53%)
Metastatic lymph node ratio 0.16 (0.06–0.26) 0.13 (0.04–0.25) 0.19 (0.01–0.29) 0.007
Metastatic lymph node ratio
 0 36 24 (67%) 12 (33%) 0.005
 < 0.10 26 20 (77%) 6 (23%)
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(69%) were found at a CAR of 0.2. However, this result 
should be interpreted with caution since cut-off levels are 
rather heterogeneous in the literature. In a recent meta-
analysis aiming to determine the potential role of CAR 
as a prognostic indicator in pancreatic cancer, the cut-off 
value of CAR ranged between 0.04 and 3.85 within the 
included studies [16]. Furthermore, both high CRP and 
low albumin were associated with poor survival, but only 
CRP was an independent prognostic factor for overall 
survival, indicating that the prognostic value of CAR is 
mainly driven by CRP. There is increasing understand-
ing of the mechanism of the relation between the CAR 
and survival in patients with cancer. C-reactive protein 
is a marker of inflammation, and an elevated serum level 
might be caused by tumour necrosis or local tissue dam-
age [9]. In addition, an elevated CRP could be a marker 
for a beneficial environment for the origin and growth of 
metastases. An elevated CRP gives an upregulation of the 
vascular endothelial growth factor, which promotes the 
growth and proliferation of tumours [7]. In addition, CRP 
is produced in response to elevated interleukin-6 levels 
[8]. Interleukin-6 promotes tumour growth by induc-
ing multiple signalling pathways, including proliferation, 
angiogenesis and metabolism [23]. Hypoalbuminemia is 
often thought to reflect malnutrition in patients. How-
ever, emerging evidence shows that a low albumin level 
may also be a reflection of an inflammatory state [24]. 
The exact cause of low albumin levels in patients with 
cancer is unclear. The literature suggests that it is a com-
bination of several mechanisms. One explanation is that 
high interleukin-6 levels produced by cancer cells inhibit 
the synthesis of albumin [25]. Alternatively, it may be 
the result of an increase in vascular permeability, which 
causes a redistribution of albumin, leading to lower 
serum levels and high extra vascular fluid levels [26, 27]. 
In accordance with the literature, men had a lower overall 
survival than women did [28–30]. It is well known that 
pancreatic cancer occurs more frequently in men. The 
underlying cause remains unclear. Possible explanations 
include differences in environmental or occupational risk 
factors, but other lifestyle factors, such as heavy smok-
ing and high alcohol intake in men, may also contribute 
[31]. Alternatively, undiscovered genetic factors may 
play a role. These possible factors were assumed to also 
contribute to a higher mortality risk. In a recent review 
of clinical prediction models for survival after pancre-
atic cancer surgery, it was found that tumour size, lymph 
node status, resection margin and differentiation grade 
were most often included in the final prediction models 
[17]. In this study, all these variables were analysed, and 
the multivariate analysis showed that, of these variables, 
only differentiation grade and para-aortic lymph node 
status were significantly associated with overall survival. 
In the same review, it was also suggested to include neo-
adjuvant therapy in the analyses. In our study, neo-adju-
vant therapy had no significant predictive value, probably 
due to the small number (n = 6) of patients receiving 
neo-adjuvant therapy. However, the role of neo-adjuvant 
therapy is currently being investigated in the PREO-
PANC II trial and the CAR in these patients could be the 
subject of research in the near future. Moreover, Strijker 
and others have recommended to include the location of 
the tumour in the pancreas as a variable since previous 
studies have demonstrated differences in tumour biology 
between tumours in the head and corpus/tail [32, 33]. In 
our study, no statistical difference in overall survival was 
observed between head and distal pancreatic resections. 





n = 90 (55%)
CAR ≥ 0.2
n = 73 (45%)
P value
 ≥ 0.10 101 46 (45%) 55 (55%)
Para-aortic lymph node
 No metastasis 152 85 (56%) 67 (44%) 0.543
 One or more metastases 11 5 (45%) 6 (55%)
Radicality 2 unknown
 R0 94 53 (56%) 41 (44%) 0.726
 R1 64 35 (55%) 39 (45%)
 R2 3 1 (33%) 2 (67%)
Adjuvant therapy 5 unknown
 No 56 28 (50%) 28 (50%) 0.246
 Yes 102 61 (60%) 41 (40%)
ASA American Society of Anesthesiologists, ECOG Eastern Cooperative Oncology Group scale of performance, CEA carcinoembryonic antigen, CA 19-9 carbohydrate 
antigen 19-9, PPPD pylorus-preserving pancreatoduodenectomy, PD pancreatoduodenectomy, SD standard deviation, IQR interquartile range
a pancreatoduodenectomy vs. other pancreas resections: p = 0.171
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Table 2 Univariate and  multivariate analyses using Cox multiple regression for  overall survival. Variables presented 
under multivariate analysis represent the final model after stepwise exclusion
Covariate Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Sex
 Female 1 1
 Male 0.632 0.432–0.923 0.018a 1.977 1.191–3.282 0.001
Age (years) 1.034 1.011–1.059 0.004a 1.062 1.030 –1.094 < 0.001
ASA
 I–II 1
 III–IV 1.374 0.923–2.044 0.117
ECOG grade
 0–1 1
 2–4 1.634 0.971–2.748 0.064a
Haemoglobin 0.961 0.805–1.148 0.661
Bilirubin 1.000 0.999–1.001 0.833b
CRP 1.011 1.002–1.020 0.022
Albumin 0.952 0.920–0.986 0.006
CAR 1.406 1.038–1.905 0.028a 1.745 1.200–2.539 0.004
mGPS
 0 1
 1 1.419 0.946–2.128 0.090
 2 1.953 0.971–3.929 0.061
CEA 1.011 0.999–1.022 0.074
CA 19.9 1.215 0.940–1.570 0.138
Supplementary nutrition
 No 1
 Enteral 1.264 0.838–1.905 0.264
 Parenteral 1.612 0.588–3.789 0.272
Neoadjuvant therapy
 No 1
 Yes 0.541 0.171–1.710 0.296b
Approach
 Open or conversion 1
 Laparoscopy 0.937 0.380–2.306 0.887
Type resection
 Pancreas head 1
 Pancreas other 1.187 0.756–1.865 0.456 b
Complication
 Clavien–Dindo 0-2 1
 Clavien–Dindo 3-5 1.266 0.778–2.059 0.342
Tumour size 1.007 0.996–1.018 0.237 b
Differentiation grade
Well or moderate 1 1
Poorly 1.271 0.837–1.931 0.261b 2.812 1.627–4.861 < 0.001
Metastatic lymph node ratio 2.946 1.154–7.521 0.024a
Para-aortic lymph node
 No metastasis 1
 One or more metastases 3.299 1.738–6.262 < 0.001a 4.489 1.883–10.702 < 0.001
Radicality
 R0 1
 R1–R2 1.386 0.952–2.018 0.089a
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objectively predict the outcome for pancreatic tumours, 
a distinction between different types of pancreatic and 
periampullary tumours should be made. Our study had 
several important strengths: we included only PDACs; 
we made a distinction between tumour locations; and 
we confirmed patients’ survival status using the national 
Personal Records Database. Our study was limited, how-
ever, by its retrospective nature, which among other 
consequences, resulted in the limited availability of labo-
ratory results and confounding factors like preoperative 
pancreatitis, cholangitis or biliary drainage. Since biliary 
drainage might influence CRP, it may have been appro-
priate to include this variable. We did, however, include 
in the analyses the bilirubin level, which had no signifi-
cant association with overall survival and did not influ-
ence the outcome. Over the last decades, variables used 
to assess the immune system and inflammation have 
gained interest as prognostic biomarkers for the pre-
diction of outcomes for pancreatic cancer [2–7]. Since 
immunotherapy may play an important role in the future 
treatment of pancreatic cancer, our study and future 
research concerning pre-treatment prognostic (systemic 
inflammatory) variables could be of significant value [34]. 
Other possible reliable pre-treatment prognostic factors 
of outcomes for pancreatic cancer, besides CAR, are sex 
[28–30], CA 19-9 [17], LDH [35], age [17], tumour loca-
tion [32], tumour size [36] and imaging texture features 
of the pancreatic tumour [37, 38]. Future research should 
focus on the development of a prediction model which 
includes pre-treatment prognostic factors. A predic-
tion model based on pre-treatment parameters is essen-
tial for optimal patient management, based on informed 
shared decision-making processes, clinical trial design 
and interpretation of results. In conclusion, this study 
showed that an elevated ultimate CAR was indepen-
dently and significantly associated with decreased overall 
survival in patients with PDAC after pancreatic resec-
tion. The CAR may, therefore, be of additional value to 
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Table 3 Number of  patients who did survive and  did 
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to-albumin ratio (CAR) with a cut-off value of 0.2
CAR < 0.2 CAR ≥ 0.2 Total
Alive 35 15 50
Deceased 55 58 113
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Fig. 2 Overall survival of patients with low (< 0.2) and high 
(≥ 0.2) C-reactive protein-to-albumin ratios, corrected for age, sex, 
differentiation grade, and positive para-aortic lymph nodes using Cox 
regression
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